Dubai, United Arab Emirates (CNN) — In late-stage clinical trials, A “peanut patch” has shown promise in young children with a peanut allergy, according to a new study.
Researchers from French biopharmaceutical company DBV Technologies and institutions around the world conducted a randomized, double-blind trial of the Viaskin Peanut patch among children, ages 1 to 3, diagnosed with a peanut allergy, according to the New England Journal of Medicine. Medical, Wed.
The experiment included 362 children from 8 countries.
And 244 of them were randomly assigned to receive a Viaskin patch, which contained 250 micrograms of peanut protein. And 118 children received a dummy patch.
On a daily basis, the children put peanut patches between their shoulders for a year, before any examinations.
And it turned out that children, who have less allergies, can eat 3 or 4 peanuts. And children with higher levels of peanut sensitivity can eat just one bean.
Almost all of the study participants experienced adverse symptoms, such as redness, itching, and swelling. Serious cases were reported in 21 children using Viaskin patches, and three in the placebo group.-
During the study period, a serious allergic reaction known as anaphylaxis was reported among 7.8% of the Viaskin patch recipients, and 3.4% of the children given the placebo.-
Only 4 had treatment-related reactions.
8 participants withdrew from the trial due to undesirable results.
The researchers note that their study has many limitations, including the exclusion of children with strong allergic reactions for safety reasons, and a lack of ethnic diversity among the participants.
It is estimated that 2.5% of American children may have a peanut allergy, and only 20% will eventually outgrow it.
An oral treatment called Palforzia is approved for children ages 4 to 17 with a peanut allergy, but there are no options available for younger children.
“Parents and caregivers are eagerly awaiting FDA-approved treatment options for this age group,” DBV CEO Daniel Tassi said in a press release.